Abstract: A method for at least one of protecting skin and promoting wound healing is provided. The method comprises administering to a subject in need an effective amount of Poria cocos extract, dehydropachymic acid (DPA), pachymic acid (PA), dehydrotumulosic acid (DTA), tumulosic acid (TA), polyporenic acid C (PAC), 3-epi-dehydrotumulosic acid (EDTA), dehydrotrametenolic acid (DTTA), trametenolic acid (TTA), dehydroeburicoic acid (DEA), eburicoic acid (EA), poricoic acid A (PAA) and/or poricoic acid B (PAB).

Abstract: A method for at least one of protecting skin and promoting wound healing is provided. The method comprises administering to a subject in need an effective amount of Poria cocos extract, dehydropachymic acid (DPA), pachymic acid (PA), dehydrotumulosic acid (DTA), tumulosic acid (TA), polyporenic acid C (PAC), 3-epi-dehydrotumulosic acid (EDTA), dehydrotrametenolic acid (DTTA), trametenolic acid (TTA), dehydroeburicoic acid (DEA), eburicoic acid (EA), poricoic acid A (PAA) and/or poricoic acid B (PAB).

Abstract: A method for regulating blood glucose level is provided. The method comprises administering to a subject in need an effective amount of at least one of poricoic acid A and poricoic acid B, wherein at least one of poricoic acid A and poricoic acid B can be used in the form of a plant extract, and wherein in the plant extract, poricoic acid A and poricoic acid B are present in a total amount of at least 30 wt %, based on the total weight of the plant extract.

Abstract: The present invention discloses a novel use of a lanostane having the following formula (I) in enhancing uptake of nutrients: wherein R1 is either H or CH3; R2 is OCOCH3, ?O or OH; R3 is H or OH; R4 is —C(?CH2)—C(CH3)2Ra, in which Ra is H or OH, or —CH?C(CH3)—Rb, in which Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.

Abstract: The present invention provides a pharmaceutical composition for the treatment and prophylaxis of angina and myocardial infarction, wherein a combination of a tea extract (catechins) and an antianginal drug are proved therapeutically potent in treating angina and mycocardial infarction induced from myocardial ischemia. The present invention also provides a use of a tea extract (catechins) in treating and preventing angina.

Abstract: A method for providing a K2-enriched FU-LING extract is provided. The method comprises the following steps: (a) mixing a FU-LING with a solvent to provide a first mixture; (b) alkalizing the first mixture to provide a second mixture; (c) acidifying the second mixture to provide a third mixture, (d) alkalizing the third mixture to provide a fourth mixture, wherein the fourth mixture has a pH value of more than 7; and (e) neutralizing the forth mixture, wherein the K2 is at least one of tumulosic acid, dehydrotumulosic acid, polyporenic acid C and 3-epi-dehydrotumulosic acid.

Abstract: A method for providing a K2-enriched FU-LING extract is provided. The method comprises the following steps: (a) mixing a FU-LING with a solvent to provide a first mixture; (b) alkalizing the first mixture to provide a second mixture; (c) acidifying the second mixture to provide a third mixture, (d) alkalizing the third mixture to provide a forth mixture, wherein the forth mixture has a pH value of more than 7; and (e) neutralizing the forth mixture, wherein the K2 is at least one of tumulosic acid, dehydrotumulosic acid, polyporenic acid C and 3-epi-dehydrotumulosic acid.

Abstract: An isoacteoside derivative and forming method and uses thereof are provided. The isoacteoside derivative has the structure of formula (I): in formula (I), R1 and R2 being independently selected from hydrogen, halogen, hydroxy group, or hydrocarboxyl group, R3 and R4 being independently selected from hydroxy group, hydrocarboxyl group, or acyloxy group, and R5 being independently selected from hydroxy group or acyloxy group.

Abstract: A pharmaceutical composition for treating diabetes is provided in this invention. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the lanostane compounds by weight of the extract, and is devoid of secolanostane.

Abstract: A pharmaceutical composition containing isoacteoside to the acteoside is provided, which is able to inhibit formation, accumulation or aggregation of amyloid ? peptides, and is thus useful in preventing or treating amyloid beta peptide-associated diseases or conditions, wherein a weight ratio of the isoacteoside to the acteoside is 4:1 to 1:4.

Abstract: A pharmaceutical composition is used to enhance immunity of the human body. The composition contains potent components of lanostane compounds. A method is devised to obtain an extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The extract contains 5-60% of the lanostane compounds by weight of the extract. The extract is devoid of secolanostane capable of inhibiting immunity development.

Abstract: A pharmaceutical composition for treating cachexia, and in particular for treating cancer cachexia. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the lanostane compounds by weight of the extract, and is devoid of secolanostane.

Abstract: The present invention provides a pharmaceutical composition for the treatment and prophylaxis of angina and myocardial infarction, wherein a combination of a tea extract (catechins) and an antianginal drug are proved therapeutically potent in treating angina and mycocardial infarction induced from myocardial ischemia. The present invention also provides a use of a tea extract (catechins) in treating and preventing angina.

Abstract: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.

Abstract: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.

Abstract: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.

Abstract: A method of treating a disease associated with cartilage defect in a subject in need thereof by administering to the subject an effectively amount of a cycloartane compound of Formula (I).

Abstract: Isoacteoside or a pharmaceutically acceptable salt thereof is used to prevent or treat amyloid beta peptide-associated diseases or conditions as an agent for inhibiting formation, accumulation or aggregation of amyloid beta peptides.

Abstract: A method for skin care includes administering the water insoluble fraction of Astragalus membranaceus, or astragaloside compounds thereof to a subject in need thereof at an effective amount for improving skin texture, reducing wrinkles, UV protection, and/or providing an anti-aging effect.

Abstract: A pharmaceutical composition for treating diabetes is provided in this invention. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the lanostane compounds by weight of the extract, and is devoid of secolanostane.